Product Code: A13858
The global cell line and membrane market was valued at $4,533.04 million in 2021, and is projected to reach $10,574.56 million by 2031, registering a CAGR of 8.8% from 2022 to 2031.A cell line is a permanently established cell culture that will multiply indefinitely in a given appropriate fresh medium and space and is frequently used to investigate biological processes in place of primary cells. Transfection, selection, and single-cell cloning are all a part of the cell line generation process. Various types of cells are used to create different cell lines. Cell lines allow for the gradual changes in cell structure, physiology, and genetic makeup in a controlled setting. . Cell lines are derived from single cells and are used to make fusion proteins, monoclonal antibodies, and vaccines.
Cell lines have revolutionized scientific research and they are widely used in the production of vaccine, testing drug metabolism & cytotoxicity, antibody production, study of gene function, generation of artificial tissues (artificial skin), and synthesis of biological compounds (therapeutic proteins).
The key factors that drive the growth of market are rise in the prevalence of cancer & chronic diseases, rise in geriatric population, and increase in number of vaccine production. In addition, the rise in novel drug development activities, growth in use of mammalian cell for cell line production, and surge in technological advancements in expression vector design are the key factors that boost the market growth. For instance, according to the International Agency of Cancer Research, 9,503,710 new cancer cases were diagnosed in Asia in 2020.
However, the strict regulatory framework coupled with the time-consuming process for the development of stable lines hampers the market growth. Conversely, emerging healthcare market in developing countries & low-income countries and increase in the risk of pandemic & communicable diseases are expected to provide lucrative opportunity for the growth of market during the forecast period.
The cell line and membrane market is segmented on the basis of product, source, type, end user, and region. By product, the market is fragmented into media & reagents, equipment, accessories, and consumables. By source, it is bifurcated into mammalian cell line and non-mammalian cell line. On the basis of type, the market is categorized into recombinant cell type, hybridomas, continuous cell line and primary cell line. By end user, the market is divided into biotech companies, academic and research institutes and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for a majority of the cell line and membrane market share in 2021 and is anticipated to remain dominant during the forecast period owing to rise in the prevalence of cancer, increased use of media & reagents for cell line development, and presence of major key players in the region.
Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to rise in prevalence of chronic diseases and increase in geriatric population in developing countries.
The key players that operate in the cell line and membrane market are Advanced Instruments LLC, AGC Biologics, Cytiva Lifesciences, Sartorius Cellgenix Gmbh, Premas Biotech, Selexis SA, Lonza, Samsung Biologics, PromoCell, Thermofisher Scientific Inc, Imegenex India Pvt. Ltd., and ProBioGen
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cell line and membrane market analysis from 2021 to 2031 to identify the prevailing cell line and membrane market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cell line and membrane market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cell line and membrane market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Products
- Media and Reagents
- Type
- Serum
- Media
- Reagents
- Equipments
- Type
- Biosafety Cabinets
- Cell Counters and Viability Systems
- Incubators
- Centrifuges
- Bioreactors
- Storage Equipment
- Others
- Accessories and Consumables
By Source
- Non Mammalian Cell Line
- Mammalian Cell Line
By Type
- Hybridomas
- Continuous cell lines
- Recombinant cell lines
- Primary cell lines
By End User
- Biotechnology and Pharmaceutical Industries
- Academic and Research Institutes
- Others
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
- Key Market Players
- Advanced Instruments LLC
- AGC Biologics
- Cytiva Lifesciences
- Sartorius
- Cellgenix Gmbh
- Premas Biotech
- Selexis SA
- Samsung Biologics
- Lonza
- Thermofisher Scientific Inc
- PromoCell
- ProBioGen
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: CELL LINE AND MEMBRANE MARKET, BY PRODUCTS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Media and Reagents
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Media and Reagents Cell Line and Membrane Market by Type
- 4.2.4.1 Serum Market size and forecast, by region
- 4.2.4.2 Media Market size and forecast, by region
- 4.2.4.3 Reagents Market size and forecast, by region
- 4.3 Equipments
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Equipments Cell Line and Membrane Market by Type
- 4.3.4.1 Biosafety Cabinets Market size and forecast, by region
- 4.3.4.2 Cell Counters and Viability Systems Market size and forecast, by region
- 4.3.4.3 Incubators Market size and forecast, by region
- 4.3.4.4 Centrifuges Market size and forecast, by region
- 4.3.4.5 Bioreactors Market size and forecast, by region
- 4.3.4.6 Storage Equipment Market size and forecast, by region
- 4.3.4.7 Others Market size and forecast, by region
- 4.4 Accessories and Consumables
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
CHAPTER 5: CELL LINE AND MEMBRANE MARKET, BY SOURCE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Non Mammalian Cell Line
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Non Mammalian Cell Line Cell Line and Membrane Market by Type
- 5.2.4.1 Insects Market size and forecast, by region
- 5.2.4.2 Amphibians Market size and forecast, by region
- 5.3 Mammalian Cell Line
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
CHAPTER 6: CELL LINE AND MEMBRANE MARKET, BY TYPE
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Recombinant cell lines
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Primary cell lines
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Hybridomas
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Continuous cell lines
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
CHAPTER 7: CELL LINE AND MEMBRANE MARKET, BY END USER
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Biotechnology and Pharmaceutical Industries
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Academic and Research Institutes
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
- 7.4 Others
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
CHAPTER 8: CELL LINE AND MEMBRANE MARKET, BY REGION
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Products
- 8.2.2.1 North America Media and Reagents Cell Line and Membrane Market by Type
- 8.2.2.2 North America Equipments Cell Line and Membrane Market by Type
- 8.2.3 North America Market size and forecast, by Source
- 8.2.3.1 North America Non Mammalian Cell Line Cell Line and Membrane Market by Type
- 8.2.4 North America Market size and forecast, by Type
- 8.2.5 North America Market size and forecast, by End User
- 8.2.6 North America Market size and forecast, by country
- 8.2.6.1 U.S.
- 8.2.6.1.1 Market size and forecast, by Products
- 8.2.6.1.2 Market size and forecast, by Source
- 8.2.6.1.3 Market size and forecast, by Type
- 8.2.6.1.4 Market size and forecast, by End User
- 8.2.6.2 Canada
- 8.2.6.2.1 Market size and forecast, by Products
- 8.2.6.2.2 Market size and forecast, by Source
- 8.2.6.2.3 Market size and forecast, by Type
- 8.2.6.2.4 Market size and forecast, by End User
- 8.2.6.3 Mexico
- 8.2.6.3.1 Market size and forecast, by Products
- 8.2.6.3.2 Market size and forecast, by Source
- 8.2.6.3.3 Market size and forecast, by Type
- 8.2.6.3.4 Market size and forecast, by End User
- 8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Products
- 8.3.2.1 Europe Media and Reagents Cell Line and Membrane Market by Type
- 8.3.2.2 Europe Equipments Cell Line and Membrane Market by Type
- 8.3.3 Europe Market size and forecast, by Source
- 8.3.3.1 Europe Non Mammalian Cell Line Cell Line and Membrane Market by Type
- 8.3.4 Europe Market size and forecast, by Type
- 8.3.5 Europe Market size and forecast, by End User
- 8.3.6 Europe Market size and forecast, by country
- 8.3.6.1 Germany
- 8.3.6.1.1 Market size and forecast, by Products
- 8.3.6.1.2 Market size and forecast, by Source
- 8.3.6.1.3 Market size and forecast, by Type
- 8.3.6.1.4 Market size and forecast, by End User
- 8.3.6.2 France
- 8.3.6.2.1 Market size and forecast, by Products
- 8.3.6.2.2 Market size and forecast, by Source
- 8.3.6.2.3 Market size and forecast, by Type
- 8.3.6.2.4 Market size and forecast, by End User
- 8.3.6.3 UK
- 8.3.6.3.1 Market size and forecast, by Products
- 8.3.6.3.2 Market size and forecast, by Source
- 8.3.6.3.3 Market size and forecast, by Type
- 8.3.6.3.4 Market size and forecast, by End User
- 8.3.6.4 Italy
- 8.3.6.4.1 Market size and forecast, by Products
- 8.3.6.4.2 Market size and forecast, by Source
- 8.3.6.4.3 Market size and forecast, by Type
- 8.3.6.4.4 Market size and forecast, by End User
- 8.3.6.5 Spain
- 8.3.6.5.1 Market size and forecast, by Products
- 8.3.6.5.2 Market size and forecast, by Source
- 8.3.6.5.3 Market size and forecast, by Type
- 8.3.6.5.4 Market size and forecast, by End User
- 8.3.6.6 Rest of Europe
- 8.3.6.6.1 Market size and forecast, by Products
- 8.3.6.6.2 Market size and forecast, by Source
- 8.3.6.6.3 Market size and forecast, by Type
- 8.3.6.6.4 Market size and forecast, by End User
- 8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Products
- 8.4.2.1 Asia-Pacific Media and Reagents Cell Line and Membrane Market by Type
- 8.4.2.2 Asia-Pacific Equipments Cell Line and Membrane Market by Type
- 8.4.3 Asia-Pacific Market size and forecast, by Source
- 8.4.3.1 Asia-Pacific Non Mammalian Cell Line Cell Line and Membrane Market by Type
- 8.4.4 Asia-Pacific Market size and forecast, by Type
- 8.4.5 Asia-Pacific Market size and forecast, by End User
- 8.4.6 Asia-Pacific Market size and forecast, by country
- 8.4.6.1 Japan
- 8.4.6.1.1 Market size and forecast, by Products
- 8.4.6.1.2 Market size and forecast, by Source
- 8.4.6.1.3 Market size and forecast, by Type
- 8.4.6.1.4 Market size and forecast, by End User
- 8.4.6.2 China
- 8.4.6.2.1 Market size and forecast, by Products
- 8.4.6.2.2 Market size and forecast, by Source
- 8.4.6.2.3 Market size and forecast, by Type
- 8.4.6.2.4 Market size and forecast, by End User
- 8.4.6.3 Australia
- 8.4.6.3.1 Market size and forecast, by Products
- 8.4.6.3.2 Market size and forecast, by Source
- 8.4.6.3.3 Market size and forecast, by Type
- 8.4.6.3.4 Market size and forecast, by End User
- 8.4.6.4 India
- 8.4.6.4.1 Market size and forecast, by Products
- 8.4.6.4.2 Market size and forecast, by Source
- 8.4.6.4.3 Market size and forecast, by Type
- 8.4.6.4.4 Market size and forecast, by End User
- 8.4.6.5 South Korea
- 8.4.6.5.1 Market size and forecast, by Products
- 8.4.6.5.2 Market size and forecast, by Source
- 8.4.6.5.3 Market size and forecast, by Type
- 8.4.6.5.4 Market size and forecast, by End User
- 8.4.6.6 Rest of Asia-Pacific
- 8.4.6.6.1 Market size and forecast, by Products
- 8.4.6.6.2 Market size and forecast, by Source
- 8.4.6.6.3 Market size and forecast, by Type
- 8.4.6.6.4 Market size and forecast, by End User
- 8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Products
- 8.5.2.1 LAMEA Media and Reagents Cell Line and Membrane Market by Type
- 8.5.2.2 LAMEA Equipments Cell Line and Membrane Market by Type
- 8.5.3 LAMEA Market size and forecast, by Source
- 8.5.3.1 LAMEA Non Mammalian Cell Line Cell Line and Membrane Market by Type
- 8.5.4 LAMEA Market size and forecast, by Type
- 8.5.5 LAMEA Market size and forecast, by End User
- 8.5.6 LAMEA Market size and forecast, by country
- 8.5.6.1 Brazil
- 8.5.6.1.1 Market size and forecast, by Products
- 8.5.6.1.2 Market size and forecast, by Source
- 8.5.6.1.3 Market size and forecast, by Type
- 8.5.6.1.4 Market size and forecast, by End User
- 8.5.6.2 Saudi Arabia
- 8.5.6.2.1 Market size and forecast, by Products
- 8.5.6.2.2 Market size and forecast, by Source
- 8.5.6.2.3 Market size and forecast, by Type
- 8.5.6.2.4 Market size and forecast, by End User
- 8.5.6.3 South Africa
- 8.5.6.3.1 Market size and forecast, by Products
- 8.5.6.3.2 Market size and forecast, by Source
- 8.5.6.3.3 Market size and forecast, by Type
- 8.5.6.3.4 Market size and forecast, by End User
- 8.5.6.4 Rest of LAMEA
- 8.5.6.4.1 Market size and forecast, by Products
- 8.5.6.4.2 Market size and forecast, by Source
- 8.5.6.4.3 Market size and forecast, by Type
- 8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Key developments
CHAPTER 10: COMPANY PROFILES
- 10.1 Advanced Instruments LLC
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
- 10.2 AGC Biologics
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
- 10.3 Cytiva Lifesciences
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
- 10.4 Sartorius
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
- 10.5 Cellgenix Gmbh
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
- 10.6 Premas Biotech
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
- 10.7 Selexis SA
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
- 10.8 Samsung Biologics
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
- 10.9 Lonza
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments
- 10.10 Thermofisher Scientific Inc
- 10.10.1 Company overview
- 10.10.2 Company snapshot
- 10.10.3 Operating business segments
- 10.10.4 Product portfolio
- 10.10.5 Business performance
- 10.10.6 Key strategic moves and developments
- 10.11 PromoCell
- 10.11.1 Company overview
- 10.11.2 Company snapshot
- 10.11.3 Operating business segments
- 10.11.4 Product portfolio
- 10.11.5 Business performance
- 10.11.6 Key strategic moves and developments
- 10.12 ProBioGen
- 10.12.1 Company overview
- 10.12.2 Company snapshot
- 10.12.3 Operating business segments
- 10.12.4 Product portfolio
- 10.12.5 Business performance
- 10.12.6 Key strategic moves and developments